Name | Enpp/Carbonic anhydrase-IN-1 |
Description | Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent inhibitor of Enpp and carbonic anhydrase, exhibiting IC50s of 1.36, 1.35, 3.00, 0.88, and 1.02 µM for NPP1, NPP2, NPP3, CA-II, and CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 also demonstrates selective antiproliferative activity for cancer cells. |
In vitro | Enpp/Carbonic anhydrase-IN-1 (0-100 µM; ) inhibits cancer cells growth with IC50s of 0.32, 0.40, 0.40, 0.58, 0.87, 0.96 µM for K-562, RPMI-8226, HT-29, SR, COLO 205, SF-539 cells, respectively. Enpp/Carbonic anhydrase-IN-1 (0-2 µM) exhibits low cytotoxic against normal skin fibroblast cells (F180) and normal breast epithelial cells (HME1) with IC50s of > 50 μM. Enpp/Carbonic anhydrase-IN-1 (0.32 µM, 0.64 µM) induces apoptosis in a dose-dependent manner at K-562 cells[1]. |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 90.0 mg/mL (218.7 mM), Sonication and heating to 50℃ are recommended.
|
Keywords | Enpp/CarbonicanhydraseIN1 | Enpp/Carbonic anhydrase-IN-1 |
Inhibitors Related | Benzenesulfonamide | Theophylline monohydrate | Cyclamic acid sodium | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Doxofylline |
Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |